EcoDrugPlus


Keyword(s):	Human Metabolites
Molecule Category	Free-form
EPA CompTox	DTXSID30945652

Keyword(s):

Human Metabolites

Molecule Category

Free-form

EPA CompTox

DTXSID30945652


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70


InChI Key	QBCSWYQAQBHPRM-UHFFFAOYSA-N
Smiles	OC1(C)CCC2C3CCC4N5NC=CC5=CCC4(C)C3CCC21C
InChI	InChI=1/C21H32N2O/c1-19-10-6-14-9-13-22-23(14)18(19)5-4-15-16(19)7-11-20(2)17(15)8-12-21(20,3)24/h6,9,13,15-18,22,24H,4-5,7-8,10-12H2,1-3H3

InChI Key

QBCSWYQAQBHPRM-UHFFFAOYSA-N

Smiles

OC1(C)CCC2C3CCC4N5NC=CC5=CCC4(C)C3CCC21C

InChI

InChI=1/C21H32N2O/c1-19-10-6-14-9-13-22-23(14)18(19)5-4-15-16(19)7-11-20(2)17(15)8-12-21(20,3)24/h6,9,13,15-18,22,24H,4-5,7-8,10-12H2,1-3H3

Property Name	Value
Molecular Formula	C21H32N2O
Molecular Weight	328.25
AlogP	3.97
Hydrogen Bond Acceptor	3.0
Hydrogen Bond Donor	2.0
Number of Rotational Bond	0.0
Polar Surface Area	35.5
Molecular species	None
Aromatic Rings	0.0
Heavy Atoms	24.0

Property Name

Value

Molecular Formula

C21H32N2O

Molecular Weight

328.25

AlogP

3.97

Hydrogen Bond Acceptor

3.0

Hydrogen Bond Donor

2.0

Number of Rotational Bond

0.0

Polar Surface Area

35.5

Molecular species

None

Aromatic Rings

0.0

Heavy Atoms

24.0

Resources	Reference
CAS NUMBER	22957-48-8
NORMAN SUSDAT
PubChem	90852

Resources

Reference

CAS NUMBER

22957-48-8

NORMAN SUSDAT

PubChem

90852


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

(17ß)-17-METHYL-2'H-ANDROST-2-ENO[3,2-C]PYRAZOL-17-OL

Structure

Physicochemical Descriptors

Cross References